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Introduction: Oral mucositis is regarded by patients as one of the worst and debilitating complications of conditioning and 
hematopoietic cell transplantation (HCT). Prevention of mucositis is one of the priorities of supportive therapy during and after 
conditioning. Objectives: The primary objective of the study was the analysis of efficacy of keratinocyte growth factor (KGF, palifermin) 
used in prophylaxis of oral mucositis in patients undergoing allo-HCT. The secondary objectives of the study included the analysis of 
the influence of palifermin on clinical course of oral mucositis and early transplant outcomes, as well as analysis of the contraindications 
of palifermin in patients undergoing allo-HCT. Patients and methods: A total number of 253 allo-HCT performed between 2003 and 
2018 in patients aged 0–19 years in a single center were analyzed. Overall, in 161 HCTs, palifermin was administered. Results: Patients 
receiving KGF were transplanted earlier in the context of calendar year, and more often received ATG, mainly due to the higher rate 
of unrelated donor transplants. Allo-HCT patients who were administered palifermin had shorter time of mucositis (median: 9 vs. 13 
days, p < 0.001), lower mucositis grade (median: 2° vs. 3°; p < 0.001), shorter period of total parenteral nutrition (median: 19 vs. 22 days; 
p = 0.018), and lower incidence of episodes of febrile neutropenia (median: 39.1% vs. 83.1%; p < 0.001). Conclusions: The use of palifermin 
has decreased duration and severity of oral mucositis in children after allo-HCT. Palifermin is a safe and well-tolerated compound in 
children undergoing allo-HCT.
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Introduction
Oral mucositis (OM) is a painful inflammation and ulceration of the 
mucous membrane. It is considered to be one of the most common 
problems associated with cancer and hematopoietic cell transplantation 
(HCT) therapy. OM is regarded by patients as one of the worst and 
debilitating complication of conditioning and transplantation [1, 2]. The 
overall incidence of OM in HCT patients is reported to be from 75% to 
100% [3–7].
Almost in all patients, a severe mucositis of III/IV° is observed after 
myeloablative conditioning [8]. The most toxic conditioning leading to OM 
are total body irradiation (TBI)-based, busulfan-based, and carmustine, 
etoposide, cytarabine, and melphalan (BEAM) conditioning [6, 9, 10]. 
During conventional chemotherapy, patients with acute lymphoblastic 
leukemia, acute myeloblastic leukemia, and non-Hodgkin’s lymphoma 
are at the highest risk of developing OM [9].
A number of approaches for prevention and treatment of OM have 
been presented in the article. In a systematic review of evaluation of 
the effectiveness of prophylactic agents for treating OM in patients 
receiving chemotherapy and/or radiotherapy, results of the total 
number of 10,514 randomized participants were analyzed [11]. Ten 
interventions were shown to have helping (albeit sometimes weak) 
in either prevention or reduction of the severity of mucositis when 
compared to either a placebo or no treatment. These interventions 
included administration of recombinant human keratinocyte growth 
factor (KGF, palifermin), cryotherapy, amifostine, granulocyte-colony 
stimulating factor (G-CSF), aloe vera, laser, intravenous glutamine, 
sucralfate, honey, and polymixin/tobramycin/amphotericin (PTA) 
antibiotic pastille/paste [11].
Therapeutic methods for oral mucositis recommended by Multinational 
Association of Supportive Care in Cancer/International Society of 
Oral Oncology (MASCC/ISOO) are KGF [11, 12, 13], low-level laser 
light therapy (LLLT) [11,13,14], cryotherapy [11, 13, 15], benzydamine 
[11, 13, 16], and morphine [11, 13, 17].
In the analysis of estimating the efficacy of cytokines for preventing OM 
in patients receiving chemotherapy and/or radiotherapy, the only positive 
recommendation made was the use of palifermin before conditioning 
treatment and immediately after transplantation in autologous stem cell 
transplant setting for hematological malignancies. On the other hand, a 
suggestion was made against the use of mouthwash with GM-CSF for 
the prevention of OM in the setting of high-dose chemotherapy followed 
by auto- or allo-HCT. No guideline was possible for any other cytokine 
or growth factor agents due to inconclusive evidence [12].
Current medical knowledge suggests that palifermin when used in 
prophylaxis can significantly reduce frequency and intensity of mucositis 
in patients after TBI and/or high-dose chemotherapy, whereas other 
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methods of prevention and treatment of mucositis have limited value 
in this painful complication.
Prevention of mucositis is one of the priorities of supportive therapy 
during and after conditioning. We introduced the prophylactic use of 
palifermin in patients undergoing HCT in our department in 2006. 
The primary objective of the study was the analysis of the efficacy 
of palifermin used in prophylaxis of OM in patients undergoing allo-
HCT. The secondary objectives of the study included the analysis 
of the influence of palifermin on clinical course of OM and early 
transplant outcomes, as well as the analysis of the contraindications 
of palifermin in patients undergoing allo-HCT.
Patients and methods
Study design
Analysis of efficacy and safe use of palifermin on clinical course of 
early post-transplant period as well as palifermin’s impact on short-
term transplant outcomes compared to the group of HCT patients 
who were not treated with palifermin was performed.
Patients
A total number of 253 allo-HCT transplantations performed between 
2003 and 2018 in patients aged 0–19 years in a single center were 
analyzed. Overall, palifermin was administered in 161 allo-HCTs.
Data collection
Collection of data was based on patients’ history including 
assessment of oral mucositis and the ability of the patients to swallow 
solid food and fluids, which is required for total parenteral nutrition 
(TPN). Oral mucositis was assessed everyday as a routine part of 
physical examination. Opioid use, length of TPN use, incidence of 
gastrointestinal complications, severe infection, fever, engraftment, 
and the length of hospitalization were assessed in all patients.
After completing data collection the following information were 
analyzed: age, primary diagnosis, stage of disease, source and dose 
of hematopoietic cells, CMV and EBV serologic profile of donor and 
recipient, type of donor, conditioning regimen, time to neutrophil and 
platelet engraftment, presence of acute and chronic graft-versus-
host disease (a/cGVHD), infections, TPN, and severe oral mucositis 
grade 3/4o. Also, patients in the study group were evaluated for the 
presence of adverse effects related to palifermin administration.
Grading of mucositis
Oral mucositis was assessed in 5 grades as suggested by World 
Health Organization (Tab. I). Grade I oral mucositis was described as 
patients having soreness with or without the presence of erythema. 
Grade II oral mucositis was defined as patients experiencing pain 
with the presence of erythema and ulcerations. The patient maintains 
the ability to swallow solid foods. Grade III oral mucositis was defined 
as patients experiencing severe pain and ulcers with extensive 
erythema. The patient is unable to swallow solids. Grade IV oral 
mucositis was defined as patients experiencing intolerable pain, 
often unable to speak, and oral alimentation is not possible. Grade III 
and IV oral mucositis were classified as severe. Maximum grades of 
oral mucositis were included in the analysis [18].
Keratinocyte growth factor administration
KGF (palifermin) was administered intravenously at the dose of 
60 mg/kg/day (Kepivance, Biovitrum, Stockholm, Sweden) once daily 
for 3 consecutive days before the conditioning treatment and for 3 
consecutive days after the transplantation starting from day 1 (a total 
of six doses). An interval of 24 hours was kept between the third dose 
and the beginning of conditioning, as well as between the end of graft 
infusion and the fourth dose of palifermin.
Definitions
Neutrophil engraftment was defined as the first of three consecutive 
days of absolute neutrophil counts exceeding 0.5 G/L. Platelet 
engraftment was defined as the first of three consecutive days with 
platelets more than 20 G/L with no platelet transfusions done during 
the preceding 7 days. Infections were classified as microbiologically 
documented infection (MDI) when pathogenic microorganism was 
identified; clinically documented infection (CDI) with the presence of 
signs and symptoms of inflammation at anatomic sites and pathogen 
was not identified; and fever of unknown origin (FUO) in case of fever 
without a localized source of infection or identified pathogen.
Supportive care
Uniform, standard anti-infective prophylaxis has been applied for 
patients undergoing HCT, including policies of preemptive viral 
approach. Empirical, preemptive, or targeted anti-infectious therapy 
was performed with various antifungal agents according to commonly 
accepted strategies [19–28]. Ciprofloxacin or cefuroxime axetil and 
fluconazole were applied during neutropenia unless other antibiotics 
or antifungals were used in therapy. Amoxicillin or cefuroxime axetil, 
acyclovir, and trimethoprim/sulfamethoxazole were used for anti-
infectious prophylaxis after engraftment. Antifungal prophylaxis was 
used routinely in allo-HCT patients during neutropenic phase or 
immunosuppressive therapy and fluconazole was included or, rarely, 
other azoles up to 2014; and then posaconazole or voriconazole was 
used in allo-HCT patients who are in GVHD phase or for secondary 
prophylaxis. A commercial immunoglobulin preparations were given 
in case of decreased immunoglobulin concentration during the first 
Table I. WHO grading of oral mucositis
Grade
0 1 2 3 4
No symptoms Soreness and erythema Erythema, ulcers; patients can 
swallow solid diet
Ulcers, extensive erythema; 
cannot swallow solid diet
Mucositis to the extent that 
alimentation is not possible
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month and then monthly until B-cell function recovery. Additionally, 
environmental prophylaxis was applied [29].
Bioethical issues
All patients provided standard informed consent for allo-HCT, 
data analysis, and publication. The study was approved by Local 
Bioethical Committee 591/2018.
Statistical analysis
The Mann–Whitney U-test was used for non-categorical comparisons 
and Chi-square or Fisher exact test for categorical comparisons. 
A p-value below 0.05 was considered statistically significant.
Results
Demographics
Total number of 253 allo-HCT (161 males, 92 females) patients were 
included in the analysis. In 161 transplants palifemin was used. The 
characteristics of the patients involved in the study are presented in 
table II.
Effect of palifermin on clinical course of transplantation 
and its complications
Patients receiving palifermin were transplanted earlier in 
the context of calendar year, and more often received ATG, 
mainly due to the higher rate of unrelated donor transplants 
(Tab. III). Allo-HCT patients who were administered with 
palifermin had shorter time of mucositis (median: 9 vs. 
13 days; p < 0.001), lower mucositis grade (median: 2° vs. 3°; 
p < 0.001), shorter period of TPN (median: 19 vs. 22 days; p = 0.018), 
and lower number of episodes of febrile neutropenia (median: 39.1% 
vs. 83.1%; p < 0.001). No impact of use of palifermin in acute or 
chronic GVHD incidence was observed.
Adverse events of palifermin
In general, palifermin was well-tolerated. After its administration only 
12 (7.4%) patients reported mild adverse events, including erythema 
or rash, pruritus, skin tenderness, or swelling of lips or tongue (Tab. IV).
Discussion
KGF is the first human epithelial growth factor showing protective 
activity to the damage caused by chemo- or radiotherapy. It inhibits 
apoptosis and pro-inflammatory cytokines, making cytoprotective 
effect on epithelial cells expressing receptor for KGF [1, 12]. 
Classical indication for the use of KGF included hematological 
disorders qualified to myeloablative conditioning consisting 
of chemotherapy and TBI, before auto-HCT in adult patients 
[1]. In the study of Spielberger et al., patients receiving KGF 
compared to placebo group had shorter median duration of OM 
(6 vs. 9 days), median duration of severe OM III/IV° (3 vs. 9 days; 
 p < 0.001), patient-reported soreness of the mouth and throat (area-
under-the-curve score: 29.0 vs. 46.8; p < 0.001), the median use of 
opioids (212 vs. 535 mg of morphine equivalents; p < 0.001), and the 
rate of use of total parenteral nutrition (31% vs. 55%; p < 0.001) [1]. 
In other studies, the positive effect of palifermin was shown in adults 
both after auto-HCT and allo-HCT [7, 30, 31].
The experience in pediatric setting is much lower: results of two 
studies carried out after auto-HCT showed lower incidence of grade 
Table II. Characteristics of the patients
Characteristics  n (%)
Female/Male 92 (36.4%)/161 (63.6%)























































































n – number of patients; ALL – acute lymphoblastic leukemia; AML – acute myeloblastic 
leukemia; SAA – severe aplastic anemia; PID – primary immunodeficiencies; MDS – myelo-
dysplastic syndromes; HD – Hodgkin lymphoma; CML – chronic myeloid leukemia; JMML – 
juvenile myelomonocytic leukemia; MUD – matched unrelated donor; MFD – matched family 
donor; MMUD – mismatched unrelated donor; CR – complete remission; RIC – reduced 
intensity conditioning; RTC – reduced toxicity conditioning; MAC – myeloablative condition-
ing; TBI – total body irradiation; WHO – World Health Organization
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n Value n Value
Sex: male vs. female 161 102:59 (63.4%) 92 59:33 (64.1%) 0.901
Age, years (median, range) 161 10.7 (0.4–22.3) 92 9.9 (0.6–20.9) 0.147
Time of hospitalization after HCT, days (median, range) 161 30 (8–91) 92 30 (4–79) 0.501
Year of HCT (median, range) 161 2012 (2006–2016) 92 2017 (2003–2018) 0.001
Matched family donor (MFD) 161 44 (27.3%) 92 35 (38%) 0.077
Matched donor (MFD + MUD) 161 151 (93.8%) 92 90 (97.8%) 0.147
Matched unrelated donor (MUD) 161 107 (66.5%) 92 45 (48.9%) 0.009
Weight, kg (median, range) 161 34 (5.0–93) 89 34 (6.6–85) 0.315
Height, cm (median, range) 161 138 (58–188) 85 138 (66–184) 0.404
Karnofsky/Lansky score (median, range) 161 100 (50–100) 92 100 (30–100) 0.063
Stadium of disease (CR > 1) 161 66 (41.0%) 92 33 (35.9%) 0.423
Hematopoietic cell source PB: BM 161 101 (62.7%) 92 59 (64.1%) 0.744
Conditioning RIC/RTC 161 50 (31.0%) 92 29 (31.5%) 0.939
Conditioning MAC 161 111 (68.9%) 92 63 (68.5%) 0.939
TBI 161 33 (20.5%) 92 18 (20.0%) 0.925
ATG use 161 115 (71.4%) 92 21 (23.3%) <0.001
Busulfan use 161 80 (49.7%) 92 39 (43.3%) 0.334
Treosulfan use 161 12 (7.5%) 92 9 (9.8%) 0.486
Fludarabine use 161 52 (32.3%) 92 23 (25.0%) 0.264
CMV IgG recipient 161 126 (78.3%) 92 72 (78.3%) 0.925
EBV IgG recipient 161 145 (90.1%) 92 83 (90.2%) 0.927
CMV IgG donor 161 81 (50.9%) 92 48 (52.2%) 0.775
EBV IgG donor 161 114 (70.8%) 92 62 (67.4%) 0.569
Dose MNC (108/kg) (median, range) 161 8.65 (0.41–53) 92 10.27 (0.34–35.3) 0.289
Dose CD34 (106/kg) (median, range) 160 6.41 (0.8–28.3) 92 6.66 (0.49–25.2) 0.334
Day of neutrophil engraftment
ANC > 0.5 G/L (median, range)
155 18 (11–34) 73 17 (10–27) 0.229
Day of platelet engraftment
PLT > 20 G/L (median, range)
140 16 (0–65) 65 14 (8–55) 0.136
Day of reticulocytes > 5‰ (median, range) 149 15 (9–43) 71 15 (12–40) 0.788
Severe GVHD (aGVHD 3/4° or extensive cGVHD) 160 25 (15.6%) 90 15 (16.7%) 0.830
Day of beginning of severe GVHD (median, range) 25 102 (15–160) 15 40 (20–120) 0.128
aGVHD grade 1–4 161 25 (15.5%) 92 15 (16.3%) 0.801
Grade aGVHD (median, range) 161 0 (0–4) 92 0 (0–4) 0.073
cGVHD (total) 141 25 (%) 75 9 (%) 0.205
cGVHD (limited) 141 3 (%) 75 3 (%) 0.377
cGVHD (extensive) 141 22 (%) 75 6 (%) 0.480
TPN use 161 152 (94.7%) 92 83 (90.2%) 0.212
TPN (number of days) (median, range) 161 19 (0–67) 92 22 (0–56) 0.018
Mucositis WHO grade (median, range) 161 2 (0–4) 92 3 (0–4) <0.001
Mucositis (days) (median, range) 161 9 (0–44) 89 13 (0–47) <0.001
Neutropenic fever 161 63 (39.1%) 92 76 (83.1%) <0.001
Severe infection 161 79 (49.1%) 92 39 (42.7%) 0.335
Gastrointestinal hemorrhage 161 15 (8.7%) 92 5 (5.6%) 0.380
n – number of patients; p – statistical value; TBI – total body irradiation; ATG – anti-thymocyte globulin; TPN – total parenteral nutrition; aGVHD – acute graft-versus-host disease; 
cGVHD – chronic graft-versus-host disease; KGF – palifermin
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III/IV° oral mucositis in patients receiving palifermin, although the 
other outcomes were inconclusive [32, 33]. Recently, two meta-
analyses on the use of palifermin were published [3, 5]. In the analysis 
of Mozaffari et al. [3], including both children and adults, either after 
auto- or after allo-HCT, impact of palifermin was shown neither on 
duration and severity of OM nor on occurrence of aGVHD. On the 
contrary, in the study of children on conventional chemotherapy, 
palifermin significantly reduced incidence, duration, and severity of 
mucositis [5]. Findings that palifermin could be a valid therapeutic 
tool to improve the quality of life of children suffering from leukemia 
or lymphoma or undergoing HCT were confirmed by other studies 
[15, 34, 35, 36], although the lack of effect was also documented 
[7, 30, 37].
The main message from our large cohort study is that pediatric 
allo-HCT patients receiving palifermin had shorter time of mucositis 
(median: 9 vs. 13 days, p < 0.001), lower mucositis grade (median: 
2° vs. 3°, p < 0.001), shorter period of TPN (median: 19 vs. 22 days, 
p = 0.018), and lesser number of episodes of febrile neutropenia 
(median: 39.1% vs. 83.1%, p < 0.001). With this study, we are 
confident that palifermin is beneficial for the prevention of OM in 
children who are receiving allo-HCT after conditioning therapy.
Our findings also bring economical value. The use of palifermin 
leads to decrease in TPN use and the number of episodes of febrile 
neutropenia, thus decreasing costs of antibiotic therapy. Although 
palifermin is a costly compound, it can give positive cost–benefit 
balance, which was also shown in other studies that indicate lower 
health-care resource utilization [31, 32, 37, 38]. The use of palifermin 
can indirectly decrease other transplant complications [31]. 
Nevertheless, the high cost contributed to the fact that this drug did 
not become a part of the standard supportive care in pediatric HCT, 
despite its contribution to the significantly decreased duration and 
severity of oral mucositis in children.
Over last twenty years, a large number of analyses on prevention 
and treatment of oral mucositis in patients receiving chemo- and/or 
radiotherapy were published in Cochrane Database of Systematic 
Reviews [11, 13]. Although the interpretation of all results is a 
complicated task, it has been found that palifermin is the most 
efficacious compound. Still, at present there is no particular 
intervention that may be regarded as the gold standard for the 
prevention and treatment of OM.
The use of palifermin appeared to be a safe intervention. Adverse 
events of its use, mainly erythema, rash, pruritus, mouth, and tongue 
disorders, including taste alteration, were found to be relatively mild 
and transient, both in our and other studies [1, 7, 30, 35, 39–41]. 
Based on the data from other studies [1, 7, 42] and from our 
experience, possible adverse events after the use of palifermin occur 
less frequently in children than in adults. In long-term follow-up, no 
adverse events that could be attributed to palifermin were observed, 
including development of acute myeloid leukemia, myelodysplastic 
syndrome, skin cancer, or decreased overall survival [12, 13, 43].
In conclusion, the use of palifermin has decreased the duration and 
the severity of OM in children after allo-HCT. Palifermin was a safe, 
well-tolerated compound for children who are treated with allo-HCT.
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Table IV. Adverse events after use of palifermin
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